1Department of Pharmaceutical Engineering, Faculty of Chemical and Process Engineering Technology, University Malaysia Pahang, Gambang26300, Malaysia.
2SPP School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, India.
3Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan25200, Malaysia.
4Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Malaya, 50603, KL, Malaysia.
*Corresponding Author E-mail: bdpharmaju@gmail.com
Online published on 3 June, 2021.
The telmisartan was determined in a rat plasma using developed and validated a reversed-phase high performance liquid chromatographic (HPLC). The pre-treatment of the plasma sample involving liquid-liquid extraction using ethanol as the extracting solvent. The HPLC method validation has been shown a linear calibration curve over a plasma concentrations range of 0.7 to 10μg/mL with a correlation coefficient of 0.9979, the limit of detection and the limit of quantification were determined to be 0.025μg/ml and 0.07μg/ml, respectively. The precision and accuracy were in an acceptable limit. The pharmacokinetic parameters of telmisartan were adequately evaluated following a single oral dose (4mg/kg) in Sprague-Dawley rats. The results observed conclude that the developed bioanalytical HPLC method is appropriate and applicable as an analytical tool in the pharmacokinetic study of telmisartan.
Telmisartan, HPLC, Validation, Bioanalytical method, Rat plasma
